Display options
Cite
Occhiutto ML, Freitas FR, Maranhao RC, et al. Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems. Pharmaceutics. 2012;4(2):252-75doi: 10.3390/pharmaceutics4020252.
Occhiutto, M. L., Freitas, F. R., Maranhao, R. C., & Costa, V. P. (2012). Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems. Pharmaceutics, 4(2), 252-75. https://doi.org/10.3390/pharmaceutics4020252
Occhiutto, Marcelo L, et al. "Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems." Pharmaceutics vol. 4,2 (2012): 252-75. doi: https://doi.org/10.3390/pharmaceutics4020252
Occhiutto ML, Freitas FR, Maranhao RC, Costa VP. Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems. Pharmaceutics. 2012 May 14;4(2):252-75. doi: 10.3390/pharmaceutics4020252. PMID: 24300231; PMCID: PMC3834913.
Copy Download .nbib Format: NLM
Share it on

Pharmaceutics. 2012 May 14;4(2):252-75. doi: 10.3390/pharmaceutics4020252.

Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems.

Pharmaceutics

Marcelo L Occhiutto, Fatima R Freitas, Raul C Maranhao, Vital P Costa

Affiliations

  1. Heart Institute, Medical School Hospital, University of São Paulo, São Paulo 05403-000, Brazil. [email protected].

PMID: 24300231 PMCID: PMC3834913 DOI: 10.3390/pharmaceutics4020252

Abstract

Several drug delivery systems have been proposed to overcome physiological barriers, improving ocular bioavailability. Systemic routes are seldom used due to the blood-ocular barrier. Novel drug delivery systems based on nanotechnology techniques have been developed to overcome ocular physiological barriers. This non-systematic review suggests the utilization of a transitory blood-ocular breakdown to allow the access of drugs by nanotechnology drug delivery systems via the systemic route. We discuss the possible ways to cause the breakdown of the blood-ocular barrier: acute inflammation caused by intraocular surgery, induced ocular hypotony, and the use of inflammatory mediators. The suitability of use of the systemic route and its toxic effects are also discussed in this article.

References

  1. Cancer Chemother Pharmacol. 2002 Jun;49(6):487-98 - PubMed
  2. Arch Ophthalmol. 1997 Apr;115(4):520-5 - PubMed
  3. Arch Ophthalmol. 1981 Aug;99(8):1436-44 - PubMed
  4. Drug Discov Today. 2008 Feb;13(3-4):135-43 - PubMed
  5. J Immunol. 2002 Mar 1;168(5):2483-92 - PubMed
  6. Int Ophthalmol. 2010 Oct;30(5):453-64 - PubMed
  7. Acta Ophthalmol Suppl. 1993;(211):1-52 - PubMed
  8. Jpn J Ophthalmol. 1995;39(4):368-76 - PubMed
  9. Invest Ophthalmol Vis Sci. 2011 Mar 10;52(3):1336-44 - PubMed
  10. Am J Pathol. 2012 Feb;180(2):672-81 - PubMed
  11. Invest Ophthalmol Vis Sci. 1995 Nov;36(12):2542-7 - PubMed
  12. Q J Nucl Med Mol Imaging. 2008 Sep;52(3):267-77 - PubMed
  13. Chem Soc Rev. 2011 Mar;40(3):1647-71 - PubMed
  14. Curr Opin Ophthalmol. 1994 Aug;5(4):110-6 - PubMed
  15. Mod Probl Ophthalmol. 1979;20:34-41 - PubMed
  16. Drugs Aging. 2007;24(9):733-60 - PubMed
  17. Invest Ophthalmol. 1975 Jul;14(7):556-60 - PubMed
  18. Int J Nanomedicine. 2011;6:2297-304 - PubMed
  19. Nanomedicine (Lond). 2011 Jul;6(5):815-35 - PubMed
  20. Graefes Arch Clin Exp Ophthalmol. 1998 Jan;236(1):69-74 - PubMed
  21. J Pharm Pharmacol. 2004 Jul;56(7):909-14 - PubMed
  22. Exp Eye Res. 1973 Apr;15(4):499-507 - PubMed
  23. J Pharm Pharmacol. 2004 Dec;56(12):1509-17 - PubMed
  24. J Clin Invest. 1981 Apr;67(4):1228-31 - PubMed
  25. Exp Eye Res. 1977;25 Suppl:27-63 - PubMed
  26. Adv Drug Deliv Rev. 2001 Oct 31;52(1):49-61 - PubMed
  27. Klin Monbl Augenheilkd Augenarztl Fortbild. 1958;133(5):662-70 - PubMed
  28. Curr Opin Ophthalmol. 2006 Feb;17(1):62-7 - PubMed
  29. Retina. 2004 Oct;24(5):676-98 - PubMed
  30. Pharm Res. 1998 Sep;15(9):1364-9 - PubMed
  31. Surv Ophthalmol. 1979 Mar-Apr;23(5):279-96 - PubMed
  32. Adv Drug Deliv Rev. 2008 Dec 14;60(15):1638-49 - PubMed
  33. Am J Ophthalmol. 1995 Jul;120(1):32-40 - PubMed
  34. Science. 2006 Feb 3;311(5761):622-7 - PubMed
  35. Mol Membr Biol. 2010 Oct;27(7):215-31 - PubMed
  36. Clin Exp Immunol. 1999 Mar;115(3):409-14 - PubMed
  37. Am J Ophthalmol. 1980 Feb;89(2):173-9 - PubMed
  38. Toxicol Sci. 2005 Nov;88(1):12-7 - PubMed
  39. Invest Ophthalmol Vis Sci. 2008 May;49(5):2016-24 - PubMed
  40. Lipids. 1993 Aug;28(8):691-6 - PubMed
  41. Invest Ophthalmol. 1972 Jan;11(1):35-45 - PubMed
  42. Klin Monbl Augenheilkd. 1993 Jan;202(1):14-8 - PubMed
  43. Eur J Pharm Biopharm. 2008 Mar;68(3):535-44 - PubMed
  44. Eye (Lond). 2011 Jun;25(6):694-703 - PubMed
  45. J Pept Sci. 2005 Dec;11(12):757-88 - PubMed
  46. Curr Drug Targets. 2004 Jul;5(5):449-55 - PubMed
  47. Cancer Chemother Pharmacol. 2009 Jan;63(2):281-7 - PubMed
  48. Patient Prefer Adherence. 2011;5:441-63 - PubMed
  49. Graefes Arch Clin Exp Ophthalmol. 2007 Mar;245(3):345-50 - PubMed
  50. Nanomedicine (Lond). 2011 Jul;6(5):879-98 - PubMed
  51. Immunol Invest. 1987 Mar;16(1):63-74 - PubMed
  52. Invest Ophthalmol Vis Sci. 1985 May;26(5):698-710 - PubMed
  53. Yan Ke Xue Bao. 2006 Dec;22(4):275-9 - PubMed
  54. Am J Pathol. 1983 Jan;110(1):1-12 - PubMed
  55. Nanotechnology. 2009 Dec 16;20(50):505101 - PubMed
  56. Drug Discov Today. 2008 Feb;13(3-4):144-51 - PubMed
  57. J Cataract Refract Surg. 2009 Aug;35(8):1471-2 - PubMed
  58. Int Ophthalmol Clin. 2006 Fall;46(4):141-54 - PubMed
  59. J Control Release. 2005 Jan 20;102(1):23-38 - PubMed
  60. J Drug Target. 2007 Jul;15(6):407-16 - PubMed
  61. Ocul Immunol Inflamm. 2004 Sep;12(3):169-92 - PubMed
  62. J Cardiovasc Pharmacol. 2012 Apr;59(4):308-14 - PubMed
  63. J Thorac Cardiovasc Surg. 2011 Jun;141(6):1522-8 - PubMed
  64. Curr Eye Res. 1986 Mar;5(3):231-40 - PubMed
  65. NMR Biomed. 2008 Nov;21(9):941-56 - PubMed
  66. Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2258-63 - PubMed
  67. Ophthalmology. 1995 Sep;102(9):1298-307 - PubMed
  68. Exp Eye Res. 2004 Mar;78(3):715-21 - PubMed
  69. Clin Exp Ophthalmol. 2011 Nov;39(8):725-8 - PubMed
  70. Trans Ophthalmol Soc U K. 1977 Sep;97(4):621-2 - PubMed
  71. Cancer Chemother Pharmacol. 2006 May;57(5):624-30 - PubMed
  72. Curr Opin Ophthalmol. 2010 May;21(3):178-83 - PubMed
  73. Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1149-60 - PubMed
  74. Int J Pharm. 2009 Aug 13;378(1-2):177-86 - PubMed
  75. Clin Exp Ophthalmol. 2004 Dec;32(6):626-32 - PubMed
  76. Int J Pharm. 2008 May 1;355(1-2):307-13 - PubMed
  77. J Inflamm Res. 2009;2:37-43 - PubMed
  78. Surv Ophthalmol. 2001 Nov-Dec;46(3):209-33 - PubMed
  79. Ophthalmology. 1998 Jun;105(6):951-68 - PubMed
  80. Ophthalmic Res. 2010;44(4):205-24 - PubMed
  81. Expert Rev Ophthalmol. 2010 Feb 1;5(1):75-93 - PubMed
  82. Int J Pharm. 2001 Aug 14;224(1-2):159-68 - PubMed
  83. Atherosclerosis. 2008 Apr;197(2):959-66 - PubMed
  84. Laryngoscope. 2000 Feb;110(2 Pt 1):312-7 - PubMed
  85. Jpn J Ophthalmol. 1988;32(2):143-50 - PubMed
  86. Ophthalmology. 1993 Nov;100(11):1619-23 - PubMed
  87. Clin Exp Ophthalmol. 2009 Nov;37(8):826-7 - PubMed
  88. Drugs Aging. 2011 Apr 1;28(4):267-82 - PubMed
  89. Gene Ther. 2009 May;16(5):645-59 - PubMed
  90. Am J Ophthalmol. 2004 Jan;137(1 Suppl):S3-12 - PubMed
  91. J Glaucoma. 1998 Apr;7(2):82-5 - PubMed
  92. Exp Eye Res. 1971 Nov;12(3):275-81 - PubMed
  93. Jpn J Ophthalmol. 1990;34(3):346-63 - PubMed
  94. Invest Ophthalmol Vis Sci. 1987 Mar;28(3):482-6 - PubMed
  95. Surv Ophthalmol. 2000 Jul-Aug;45(1):49-68 - PubMed
  96. Surv Ophthalmol. 1996 Sep-Oct;41(2):97-125 - PubMed
  97. Eye (Lond). 2001 Oct;15(Pt 5):583-6 - PubMed
  98. Cancer Res. 1994 Sep 1;54(17):4660-6 - PubMed
  99. Drug Discov Today. 2003 Dec 15;8(24):1112-20 - PubMed
  100. Ophthalmology. 2002 Sep;109(9):1604-6 - PubMed
  101. Prog Retin Eye Res. 2010 Jul;29(4):312-34 - PubMed
  102. Invest Ophthalmol Vis Sci. 1996 May;37(6):1199-203 - PubMed
  103. Doc Ophthalmol. 1976 Oct 15;41(2):287-327 - PubMed
  104. Nanomedicine (Lond). 2011 Jul;6(5):929-41 - PubMed
  105. Boll Chim Farm. 1996 Feb;135(2):145-6 - PubMed
  106. Invest Ophthalmol Vis Sci. 1995 Jun;36(7):1361-70 - PubMed
  107. Adv Drug Deliv Rev. 2005 Dec 14;57(15):2147-62 - PubMed
  108. Gynecol Oncol. 2005 Apr;97(1):178-82 - PubMed
  109. Acta Ophthalmol. 2008 Nov;86(7):716-26 - PubMed
  110. Compr Ophthalmol Update. 2007 Jan-Feb;8(1):29-37 - PubMed
  111. Ophthalmology. 2002 Jan;109(1):64-70 - PubMed
  112. Biomaterials. 2002 Aug;23(15):3247-55 - PubMed
  113. J Drug Target. 2001 Jun;9(3):209-21 - PubMed
  114. Ophthalmology. 1996 Feb;103(2):306-14 - PubMed

Publication Types